Vycor Medical, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 13, 2020 at 06:19 am EST
Share
Vycor Medical, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was USD 275,925 compared to USD 322,884 a year ago. Operating loss was USD 206,371 compared to USD 165,667 a year ago. Net loss was USD 198,287 compared to USD 209,609 a year ago. Basic loss per share was USD 0.01 compared to USD 0.02 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. For the nine months, sales was USD 850,430 compared to USD 1.061 million a year ago. Operating loss was USD 552,430 compared to USD 425,761 a year ago. Net loss was USD 622,122 compared to USD 575,211 a year ago. Basic loss per share was USD 0.04 compared to USD 0.04 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
